Journal article
Seventeen-year associations between diet quality defined by the health star rating and mortality in australians: The australian diabetes, obesity and lifestyle study (ausdiab)
XF Pan, DJ Magliano, M Zheng, M Shahid, F Taylor, C Julia, CN Mhurchu, A Pan, JE Shaw, B Neal, JH Wu
Current Developments in Nutrition | ELSEVIER SCIENCE INC | Published : 2020
DOI: 10.1093/cdn/nzaa157
Open access
Abstract
Background: The Health Star Rating (HSR) is the government-endorsed front-of-pack labeling system in Australia and New Zealand. Objectives: We aimed to examine prospective associations of a dietary index (DI) based on the HSR, as an indicator of overall diet quality, with all-cause and cardiovascular disease (CVD) mortality. Methods: We utilized data from the national population-based Australian Diabetes, Obesity and Lifestyle Study. The HSR-DI at baseline (1999-2000) was constructed by 1) calculation of the HSR points for individual foods in the baseline FFQ, and 2) calculation of the HSR-DI for each participant based on pooled HSR points across foods, weighted by the proportion of energy c..
View full abstractGrants
Awarded by China Postdoctoral Council International Postdoctoral Exchange Fellowship
Awarded by National Key Research and Development Program of China
Funding Acknowledgements
Supported by China Postdoctoral Council International Postdoctoral Exchange Fellowship 20180062 (to X-FP), National Key Research and Development Program of China grant 2017YFC0907504 (to AP), and the University of New South Wales Scientia Fellowship Program (to JHYW). The Australian Diabetes, Obesity and Lifestyle Study was supported by the Commonwealth Department of Health and Aged Care, Abbott Australasia Pty Ltd., Alphapharm Pty Ltd., AstraZeneca, Aventis Pharmaceutical, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly (Aust) Pty Ltd., GlaxoSmithKline, Janssen-Cilag (Aust) Pty Ltd., Merck Lipha s.a., Merck Sharp & Dohme (Aust), Novartis Pharmaceutical (Aust) Pty Ltd., Novo Nordisk Pharmaceutical Pty Ltd., Pharmacia and Upjohn Pty Ltd., Pfizer Pty Ltd., Roche Diagnostics, Sanofi Synthelabo (Aust) Pty Ltd., Servier Laboratories (Aust) Pty Ltd., BioRad Laboratories Pty Ltd., HITECH Pathology Pty Ltd., the Australian Kidney Foundation, Diabetes Australia, Diabetes Australia (Northern Territory), Queensland Health, South Australian Department of Human Services, Tasmanian Department of Health and Human Services, Northern Territory Health Services, Victorian Department of Human Services, the Victorian OIS program, and the Health Department of Western Australia.